Related references
Note: Only part of the references are listed.Anti-Inflammatory Profile of Paricalcitol in Hemodialysis Patients: A Prospective, Open-Label, Pilot Study
Juan F. Navarro-Gonzalez et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study
Dimitrios Hadjiyannakos et al.
CLINICAL KIDNEY JOURNAL (2013)
Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease
J. G. Hervas Sanchez et al.
NEFROLOGIA (2011)
Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-α and IL-8 production by human peripheral blood mononuclear cells
Theodoros Eleftheriadis et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2010)
Mineral Metabolism and Inflammation in Chronic Kidney Disease Patients: A Cross-Sectional Study
Juan F. Navarro-Gonzalez et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Role of Vitamin D in Chronic Kidney Disease
Tejas V. Patel et al.
SEMINARS IN NEPHROLOGY (2009)
Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)
Francesca Tentori et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Ratio of Paricalcitol Dosage to Serum Parathyroid Hormone Level and Survival in Maintenance Hemodialysis Patients
Christian S. Shinaberger et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Paricalcitol reduces albuminuria and inflammation in chronic kidney disease - A randomized double-blind pilot trial
Pooneh Alborzi et al.
HYPERTENSION (2008)
Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappa B signaling
Xiaoyue Tan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
The association of sudden cardiac death with inflammation and other traditional risk factors
Rulan S. Parekh et al.
KIDNEY INTERNATIONAL (2008)
Predictors of cardiovascular events in patients with end-stage renal disease:: an analysis from the Fosinopril in Dialysis study
Michele Kessler et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment
Melanie S. Joy et al.
JOURNAL OF MANAGED CARE PHARMACY (2007)
Nonclassical aspects of differential vitamin D receptor activation
Dennis Andress
DRUGS (2007)
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease
A. Levin et al.
KIDNEY INTERNATIONAL (2007)
Dissecting inflammation in ESRD: Do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients?
Carmine Zoccali et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings
DG Dobrez et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
AS Go et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The pleiotropic actions of vitamin D
R Lin et al.
BIOESSAYS (2004)
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy
M Teng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Increased mRNA expression of tumour necrosis factor-α and its converting enzyme in circulating leucocytes of patients with acute myocardial infarction
T Akatsu et al.
CLINICAL SCIENCE (2003)
Share Paper
